InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Trading Down 2.9 %

Shares of NSPR stock opened at $2.39 on Friday. The stock has a market cap of $59.46 million, a P/E ratio of -3.22 and a beta of 0.93. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42. The stock has a 50 day simple moving average of $2.59 and a 200 day simple moving average of $2.59.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new position in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD at the end of the most recent quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.